| TRIENTINE |
Cuprior® |
Orphalan |
Wilson disease |
Nov 2021 |
Not Recommended |
| SECUKINUMAB |
Cosentyx® |
Novartis Pharmaceuticals Australia Pty Limited |
Paediatric psoriasis |
Nov 2021 |
Recommended |
| RITUXIMAB |
Ruxience® |
Pfizer Australia Pty Ltd |
Non-Hodgkin’s lymphoma (NHL); Chronic lymphocytic leukaemia (CLL); Rheumatoid arthritis
(RA); Granulomatosis with polyangiitis (Wegener’s granulomatosis) (GPA); Microscopic
polyangiitis (MPA). |
Nov 2021 |
Recommended |
| TEPOTINIB |
Tepmetko® |
Merck Healthcare Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Nov 2021 |
Deferred |
| TRIENTINE |
Waymade® |
Clinect Pty Ltd |
Wilson disease |
Nov 2021 |
Not Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal
adenocarcinoma. |
Nov 2021 |
Not Recommended |
| LAROTRECTINIB |
Vitrakvi® |
Bayer Australia Ltd |
Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions |
Nov 2021 |
Deferred |
| ADALIMUMAB |
Hulio® |
Alphapharm Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa. |
Nov 2021 |
Recommended |
| IMATINIB |
Imatab |
Juno Pharmaceuticals Pty Ltd |
Chronic myeloid leukaemia (CML); Philadelphia chromosome positive acute lymphoblastic
leukaemia (Ph+ ALL); Myelodysplastic or myeloproliferative disorder (MDS/MPD); Aggressive
systemic mastocytosis (ASM) with eosinophilia; Chronic eosinophilic leukaemia (CEL)
or Hypereosinophilic syndrome (HES); Dermatofibrosarcoma protuberans (DFSP); Gastrointestinal
stromal tumour (GIST); Malignant GIST. |
Nov 2021 |
Recommended |
| BEVACIZUMAB |
Abevmy® |
Alphapharm Pty Ltd |
Relapsed or recurrent glioblastoma; Advanced (unresectable) Barcelona Clinic Liver
Cancer; Stage B or Stage C hepatocellular carcinoma; Stage IV (metastatic) non-small
cell lung cancer (NSCLC); Advanced carcinoma of cervix; Advanced International Federation
of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian,
fallopian tube or primary peritoneal cancer; Metastatic colorectal cancer. |
Nov 2021 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Squamous cell carcinoma of the head and neck (SCCHN) |
Nov 2021 |
Deferred |
| APALUTAMIDE |
Erlyand® |
Janssen-Cilag Pty Ltd |
Prostate cancer |
Nov 2021 |
Not Recommended |
| POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL |
Systane® |
Alcon Laboratories (Australia) Pty Ltd |
Severe dry eye syndrome |
Nov 2021 |
Recommended |
| DARATUMUMAB |
Darzalex® SC |
Janssen-Cilag Pty Ltd |
Amyloid light-chain (AL) amyloidosis |
Nov 2021 |
Not Recommended |
| ESSENTIAL AMINO ACIDS FORMULA WITH VITAMINS AND MINERALS |
EAA Supplement |
Vitaflo Australia Pty Limited |
Gyrate atrophy of the choroid and retina; Urea cycle disorders. |
Nov 2021 |
Recommended |
| PROGESTERONE |
Oripro® |
Orion Laboratories Pty Ltd |
Prevention of preterm birth |
Nov 2021 |
Recommended |
| FOLLITROPIN ALFA |
Gonal-f® Pen |
Merck Healthcare Pty Ltd |
Assisted reproductive technology |
Nov 2021 |
Not Recommended |
| CEMIPLIMAB |
Libtayo® |
Sanofi-aventis Australia Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Nov 2021 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Oesophageal carcinoma or HER-2-negative gastroesophageal adenocarcinoma |
Nov 2021 |
Not Recommended |
| PREGABALIN |
Lyrica® CR |
Upjohn Australia Pty Ltd |
Neuropathic pain |
Nov 2021 |
Not Recommended |
| REGORAFENIB |
Stivarga® |
Bayer Australia Ltd |
Colorectal cancer |
Nov 2021 |
Not Recommended |
| ETANERCEPT |
Rymti® |
Alphapharm Pty Ltd |
Rheumatoid arthritis; Plaque psoriasis; Ankylosing spondylitis; Psoriatic arthritis;
Juvenile idiopathic arthritis; Paediatric plaque psoriasis. |
Nov 2021 |
Recommended |
| ECULIZUMAB |
Soliris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Neuromyelitis optica spectrum disorder (NMOSD) |
Nov 2021 |
Not Recommended |
| CEMIPLIMAB |
Libtayo® |
Sanofi-aventis Australia Pty Ltd |
Squamous cell carcinoma (SCC) |
Nov 2021 |
Not Applicable |
| GEMTUZUMAB OZOGAMICIN |
Mylotarg® |
Pfizer Australia Pty Ltd |
Acute myeloid leukaemia (AML) |
Nov 2021 |
Recommended |
| MECASERMIN |
Increlex® |
Ipsen Pty Ltd |
Primary insulin-like growth factor 1 deficiency (Primary IGFD) |
Nov 2021 |
Not Recommended |
| INSULIN ASPART |
Truvelog®; Truvelog® Solostar |
Sanofi-aventis Australia Pty Ltd |
Diabetes mellitus |
Nov 2021 |
Recommended |
| OLAPARIB |
Lynparza® |
AstraZeneca Pty Ltd |
Prostate cancer |
Nov 2021 |
Recommended |
| SACITUZUMAB GOVITECAN |
Trodelvy® |
Gilead Sciences Pty Limited |
Breast cancer |
Nov 2021 |
Not Recommended |
| TRASTUZUMAB |
Herzuma® |
Celltrion Healthcare Australia Pty Ltd |
Metastatic (Stage IV) HER2 positive breast cancer; Metastatic (Stage IV) HER2 positive
adenocarcinoma of the stomach or gastroesophageal junction; Early HER2 positive breast
cancer |
Nov 2021 |
Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2021 |
Not Recommended |
| CABOTEGRAVIR/CABOTEGRAVIR AND RILPIVIRINE |
Vocabria®; Cabenuva® |
ViiV Healthcare Pty Ltd |
Human Immunodeficiency Virus (HIV) |
Nov 2021 |
Recommended |
| AMIFAMPRIDINE |
Ruzurgi® |
The Trustee For Orspec Pharma Unit Trust |
Lambert-Eaton myasthenic syndrome |
Nov 2021 |
Not Recommended |
| AVALGLUCOSIDASE ALFA |
Nexviazyme® |
Sanofi-aventis Australia Pty Ltd |
Pompe disease |
Nov 2021 |
Not Recommended |
| APALUTAMIDE |
Erlyand® |
Janssen-Cilag Pty Ltd |
Prostate cancer |
Nov 2021 |
Recommended |
| BUPRENORPHINE |
Buvidal® Weekly; Buvidal® Monthly |
Camurus Pty Ltd |
Opioid dependence |
Nov 2021 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis. |
Nov 2021 |
Recommended |
| PREGABALIN |
Pregabalin-AFT |
AFT Pharmaceuticals (Au) Pty Ltd |
Neuropathic pain |
Nov 2021 |
Deferred |
| RISANKIZUMAB |
Skyrizi® |
AbbVie Pty Ltd |
Severe chronic plaque psoriasis |
Nov 2021 |
Recommended |
| FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL |
Trelegy® Ellipta® 200/62.5/25 |
GlaxoSmithKline Australia Pty Ltd |
Severe asthma |
Nov 2021 |
Recommended |
| EMPAGLIFLOZIN |
Jardiance® |
Boehringer Ingelheim Pty Ltd |
Chronic heart failure |
Nov 2021 |
Recommended |
| OMALIZUMAB |
Xolair® |
Novartis Pharmaceuticals Australia Pty Limited |
Uncontrolled severe asthma; Severe chronic spontaneous urticaria; Uncontrolled severe
allergic asthma. |
Nov 2021 |
Not Recommended |
| MEPOLIZUMAB |
Nucala® |
GlaxoSmithKline Australia Pty Ltd |
Chronic rhinosinusitis with nasal polyps |
Nov 2021 |
Not Recommended |
| CLADRIBINE |
Mavenclad® |
Merck Healthcare Pty Ltd |
Multiple sclerosis |
Nov 2021 |
Not Recommended |
| IXEKIZUMAB |
Taltz® |
Eli Lilly Australia Pty Ltd |
Non radiographic axial spondyloarthritis (nr-axSpA) |
Nov 2021 |
Recommended |
| GILTERITINIB |
Xospata® |
Astellas Pharma Australia Pty Ltd |
Acute myeloid leukaemia (AML) |
Nov 2021 |
Not Recommended |
| ABROCITINIB |
Cibinqo® |
Pfizer Australia Pty Ltd |
Atopic dermatitis |
Nov 2021 |
Not Applicable |
| BUDESONIDE |
Jorveza® |
Dr Falk Pharma Australia Pty Ltd |
Eosinophilic oesophagitis (EoE) |
Nov 2021 |
Recommended |
| SILTUXIMAB |
Sylvant® |
Eusa Pharma (UK) Ltd |
Idiopathic multicentric Castleman’s disease (iMCD) |
Nov 2021 |
Recommended |
| RIBAVIRIN |
Ibavyr® |
Clinect Pty Ltd |
Chronic hepatitis C infection |
Nov 2021 |
Recommended |
| UPADACITINIB |
Rinvoq® |
Abbvie Pty Ltd |
Severe atopic dermatitis |
Nov 2021 |
Recommended |
| DAPAGLIFLOZIN |
Forxiga® |
AstraZeneca Pty Ltd |
Chronic kidney disease |
Nov 2021 |
Not Recommended |
| MELATONIN |
Slenyto® |
Aspen Pharmacare Australia Pty Ltd |
Insomnia |
Nov 2021 |
Recommended |
| IVERMECTIN |
Stromectol |
Merck Sharp & Dohme (Australia) Pty Ltd |
Human sarcoptic scabies |
Nov 2021 |
Recommended |
